Paper42579251
Application of nanotherapy in cardiovascular diseases featuring novel pharmacological mechanisms and drug delivery strategies.
Yang J. Discov Nano, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Application of nanotherapy in cardiovascular diseases featuring novel pharmacological mechanisms and drug delivery strategies. Papers, record 42579251. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42579251
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Application of nanotherapy in cardiovascular diseases featuring novel pharmacological mechanisms and drug delivery strategies.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References272
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28960167 | PLGA nanoparticles with CD133 aptamers for targeted delivery and sustained release of propranolol to hemangioma. | Nanomedicine (Lond) | 2017 | https://conductscience.org/library/papers/28960167 | PubMed |
| 2 | 38255922 | Aliskiren-Loaded Nanoparticles Downregulate (Pro)renin Receptor and ACE Gene Expression in the Heart of Spontaneously Hypertensive Rats: Effect on NADPH Oxidase. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38255922 | PubMed |
| 3 | 39392505 | Synthesis and characterization of molecularly imprinted polymer nanoparticles against porcine circovirus type 2 viral-like particles. | Anal Bioanal Chem | 2024 | https://conductscience.org/library/papers/39392505 | PubMed |
| 4 | 37646313 | Synergetic EGCG and coenzyme Q10 DSPC liposome nanoparticles protect against myocardial infarction. | Biomater Sci | 2023 | https://conductscience.org/library/papers/37646313 | PubMed |
| 5 | 39403576 | Recent advances of traditional Chinese medicine against cardiovascular disease: overview and potential mechanisms. | Front Endocrinol (Lausanne) | 2024 | https://conductscience.org/library/papers/39403576 | PubMed |
| 6 | 40722790 | Targeted and Biomimetic Nanoparticles for Atherosclerosis Therapy: A Review of Emerging Strategies. | Biomedicines | 2025 | https://conductscience.org/library/papers/40722790 | PubMed |
| 7 | 30660748 | Cardiovascular therapies utilizing targeted delivery of nanomedicines and aptamers. | Int J Pharm | 2019 | https://conductscience.org/library/papers/30660748 | PubMed |
| 8 | 40893381 | Self-assembled extracellular matrix-lipid nanoparticle composite for site-specific siRNA delivery to improve cardiac repair post-myocardial infarction. | Mater Today Bio | 2025 | https://conductscience.org/library/papers/40893381 | PubMed |
| 9 | 38873669 | Macrophage polarisation and inflammatory mechanisms in atherosclerosis: Implications for prevention and treatment. | Heliyon | 2024 | https://conductscience.org/library/papers/38873669 | PubMed |
| 10 | 41771322 | Apolipoprotein M: Structural insights, functional roles, and therapeutic approaches in vascular disease. | J Biol Chem | 2026 | https://conductscience.org/library/papers/41771322 | PubMed |
| 11 | 37646052 | An Overview of Nanostructured Lipid Carriers and its Application in Drug Delivery through Different Routes. | Adv Pharm Bull | 2023 | https://conductscience.org/library/papers/37646052 | PubMed |
| 12 | 39218342 | Nanomedicine: A great boon for cardiac regenerative medicine. | Eur J Pharmacol | 2024 | https://conductscience.org/library/papers/39218342 | PubMed |
| 13 | 37500736 | Uptake and anti-inflammatory effects of liposomal astaxanthin on endothelial cells tracked by Raman and fluorescence imaging. | Mikrochim Acta | 2023 | https://conductscience.org/library/papers/37500736 | PubMed |
| 14 | 36898531 | Anti-CXCR2 antibody-coated nanoparticles with an erythrocyte-platelet hybrid membrane layer for atherosclerosis therapy. | J Control Release | 2023 | https://conductscience.org/library/papers/36898531 | PubMed |
| 15 | 41674372 | Fusogenic Hybrid Gelled Nanovesicles Combining Mesenchymal Stromal Cell Cargo with Cholesterol-Modified Macrophage Membranes for Targeted Myocardial Infarction Therapy. | ACS Nano | 2026 | https://conductscience.org/library/papers/41674372 | PubMed |
| 16 | 41458564 | Engineering Optimized Nanostructured Lipid Carriers for Astaxanthin: A Response Surface Methodology Approach. | Int J Nanomedicine | 2025 | https://conductscience.org/library/papers/41458564 | PubMed |
| 17 | 41282621 | Potential of herbal formulas and bioactive metabolites in treating atherosclerosis: targeted modulation of macrophage polarization. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/41282621 | PubMed |
| 18 | 39831819 | Extracellular vesicle-mediated VEGF-A mRNA delivery rescues ischaemic injury with low immunogenicity. | Eur Heart J | 2025 | https://conductscience.org/library/papers/39831819 | PubMed |
| 19 | 35600953 | Natural Herbal Medicine as a Treatment Strategy for Myocardial Infarction through the Regulation of Angiogenesis. | Evid Based Complement Alternat Med | 2022 | https://conductscience.org/library/papers/35600953 | PubMed |
| 20 | 33782898 | Nanostructured lipid carriers of isradipine for effective management of hypertension and isoproterenol induced myocardial infarction. | Drug Deliv Transl Res | 2022 | https://conductscience.org/library/papers/33782898 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42579251
GET https://conductscience.org/api/papers/v1/42579251/references?page=2